AAPL342.92-0.55 (-0.16%) ▼|ABBV284.42-1.00 (-0.35%) ▼|ABT104.32-0.57 (-0.54%) ▼|ACN235.20+5.52 (+2.40%) ▲|ADBE246.56+1.36 (+0.55%) ▲|AMAT417.31+8.02 (+1.96%) ▲|AMD539.43+10.68 (+2.02%) ▲|AMGN428.11-4.39 (-1.01%) ▼|AMT182.00-3.28 (-1.77%) ▼|AMZN262.08+12.08 (+4.83%) ▲|AVGO335.37+6.62 (+2.01%) ▲|AXP315.88+2.29 (+0.73%) ▲|BA191.26+1.05 (+0.55%) ▲|BAC50.45-0.78 (-1.52%) ▼|BKNG161.95-1.50 (-0.92%) ▼|BLK1,125.72-8.66 (-0.76%) ▼|BMY59.10-0.65 (-1.09%) ▼|BNY143.18-0.12 (-0.08%) ▼|BRK-B532.48+0.46 (+0.09%) ▲|C122.37-1.89 (-1.52%) ▼|CAT727.56-3.20 (-0.44%) ▼|CL93.49-0.62 (-0.66%) ▼|CMCSA22.03+0.13 (+0.59%) ▲|COF199.96-1.78 (-0.88%) ▼|COP145.42-1.09 (-0.74%) ▼|COST995.54+6.43 (+0.65%) ▲|CRM242.31+1.61 (+0.67%) ▲|CSCO107.09-0.30 (-0.28%) ▼|CVS91.62-0.74 (-0.80%) ▼|CVX224.99-0.01 (0.00%) ▼|DE629.09-12.77 (-1.99%) ▼|DHR224.75-4.30 (-1.88%) ▼|DIS109.89-0.70 (-0.63%) ▼|DUK119.75-1.72 (-1.42%) ▼|EMR160.78-0.69 (-0.43%) ▼|FDX292.70-0.85 (-0.29%) ▼|GD342.86-1.38 (-0.40%) ▼|GE312.88-0.95 (-0.30%) ▼|GEV911.55-9.65 (-1.05%) ▼|GILD154.70-1.49 (-0.95%) ▼|GM82.61-1.35 (-1.61%) ▼|GOOG340.22+3.31 (+0.98%) ▲|GOOGL344.34+3.75 (+1.10%) ▲|GS875.52-5.74 (-0.65%) ▼|HD310.46+0.83 (+0.27%) ▲|HON210.47-0.95 (-0.45%) ▼|IBM236.90+4.76 (+2.05%) ▲|INTC92.51+2.66 (+2.96%) ▲|INTU325.96+0.81 (+0.25%) ▲|ISRG433.05+6.35 (+1.49%) ▲|JNJ254.24-1.33 (-0.52%) ▼|JPM334.90-4.83 (-1.42%) ▼|KO93.87-0.03 (-0.03%) ▼|LIN504.07+5.64 (+1.13%) ▲|LLY1,251.71-5.32 (-0.42%) ▼|LMT553.09+1.00 (+0.18%) ▲|LOW196.35-1.03 (-0.52%) ▼|LRCX274.09+10.15 (+3.84%) ▲|MA615.72-1.70 (-0.28%) ▼|MCD243.09+0.12 (+0.05%) ▲|MDLZ63.56-0.35 (-0.55%) ▼|MDT93.08-1.67 (-1.76%) ▼|META702.62-6.71 (-0.95%) ▼|MMM163.13-1.63 (-0.99%) ▼|MO74.79-0.32 (-0.43%) ▼|MRK144.48-1.47 (-1.01%) ▼|MS179.14-1.43 (-0.79%) ▼|MSFT534.16+5.11 (+0.97%) ▲|MU905.25+26.41 (+3.00%) ▲|NEE78.35-1.46 (-1.82%) ▼|NFLX69.52-1.01 (-1.43%) ▼|NKE37.11-0.03 (-0.07%) ▼|NOW144.64+2.67 (+1.88%) ▲|NVDA217.40+3.27 (+1.53%) ▲|ORCL130.04+1.81 (+1.41%) ▲|PEP133.22+1.73 (+1.32%) ▲|PFE29.47-0.12 (-0.39%) ▼|PG158.19-1.16 (-0.73%) ▼|PLTR194.27+8.24 (+4.43%) ▲|PM202.88-2.33 (-1.13%) ▼|QCOM173.54+1.43 (+0.83%) ▲|RTX193.17-0.75 (-0.39%) ▼|SBUX98.10+0.58 (+0.59%) ▲|SCHW89.99-1.97 (-2.14%) ▼|SO89.81-1.37 (-1.50%) ▼|SPG202.59-2.85 (-1.39%) ▼|T23.34-0.11 (-0.45%) ▼|TMO679.81-10.19 (-1.48%) ▼|TMUS157.88-1.22 (-0.77%) ▼|TSLA368.00+13.28 (+3.74%) ▲|TXN276.41-0.08 (-0.03%) ▼|UBER70.33-0.03 (-0.04%) ▼|UNH405.18+3.75 (+0.93%) ▲|UNP287.87-1.17 (-0.40%) ▼|UPS97.15-0.33 (-0.34%) ▼|USB58.17-0.57 (-0.96%) ▼|V403.61+1.00 (+0.25%) ▲|VZ44.38-0.41 (-0.92%) ▼|WFC82.48-1.39 (-1.66%) ▼|WMT119.22+0.41 (+0.34%) ▲|XOM178.67-0.31 (-0.17%) ▼|AAPL342.92-0.55 (-0.16%) ▼|ABBV284.42-1.00 (-0.35%) ▼|ABT104.32-0.57 (-0.54%) ▼|ACN235.20+5.52 (+2.40%) ▲|ADBE246.56+1.36 (+0.55%) ▲|AMAT417.31+8.02 (+1.96%) ▲|AMD539.43+10.68 (+2.02%) ▲|AMGN428.11-4.39 (-1.01%) ▼|AMT182.00-3.28 (-1.77%) ▼|AMZN262.08+12.08 (+4.83%) ▲|AVGO335.37+6.62 (+2.01%) ▲|AXP315.88+2.29 (+0.73%) ▲|BA191.26+1.05 (+0.55%) ▲|BAC50.45-0.78 (-1.52%) ▼|BKNG161.95-1.50 (-0.92%) ▼|BLK1,125.72-8.66 (-0.76%) ▼|BMY59.10-0.65 (-1.09%) ▼|BNY143.18-0.12 (-0.08%) ▼|BRK-B532.48+0.46 (+0.09%) ▲|C122.37-1.89 (-1.52%) ▼|CAT727.56-3.20 (-0.44%) ▼|CL93.49-0.62 (-0.66%) ▼|CMCSA22.03+0.13 (+0.59%) ▲|COF199.96-1.78 (-0.88%) ▼|COP145.42-1.09 (-0.74%) ▼|COST995.54+6.43 (+0.65%) ▲|CRM242.31+1.61 (+0.67%) ▲|CSCO107.09-0.30 (-0.28%) ▼|CVS91.62-0.74 (-0.80%) ▼|CVX224.99-0.01 (0.00%) ▼|DE629.09-12.77 (-1.99%) ▼|DHR224.75-4.30 (-1.88%) ▼|DIS109.89-0.70 (-0.63%) ▼|DUK119.75-1.72 (-1.42%) ▼|EMR160.78-0.69 (-0.43%) ▼|FDX292.70-0.85 (-0.29%) ▼|GD342.86-1.38 (-0.40%) ▼|GE312.88-0.95 (-0.30%) ▼|GEV911.55-9.65 (-1.05%) ▼|GILD154.70-1.49 (-0.95%) ▼|GM82.61-1.35 (-1.61%) ▼|GOOG340.22+3.31 (+0.98%) ▲|GOOGL344.34+3.75 (+1.10%) ▲|GS875.52-5.74 (-0.65%) ▼|HD310.46+0.83 (+0.27%) ▲|HON210.47-0.95 (-0.45%) ▼|IBM236.90+4.76 (+2.05%) ▲|INTC92.51+2.66 (+2.96%) ▲|INTU325.96+0.81 (+0.25%) ▲|ISRG433.05+6.35 (+1.49%) ▲|JNJ254.24-1.33 (-0.52%) ▼|JPM334.90-4.83 (-1.42%) ▼|KO93.87-0.03 (-0.03%) ▼|LIN504.07+5.64 (+1.13%) ▲|LLY1,251.71-5.32 (-0.42%) ▼|LMT553.09+1.00 (+0.18%) ▲|LOW196.35-1.03 (-0.52%) ▼|LRCX274.09+10.15 (+3.84%) ▲|MA615.72-1.70 (-0.28%) ▼|MCD243.09+0.12 (+0.05%) ▲|MDLZ63.56-0.35 (-0.55%) ▼|MDT93.08-1.67 (-1.76%) ▼|META702.62-6.71 (-0.95%) ▼|MMM163.13-1.63 (-0.99%) ▼|MO74.79-0.32 (-0.43%) ▼|MRK144.48-1.47 (-1.01%) ▼|MS179.14-1.43 (-0.79%) ▼|MSFT534.16+5.11 (+0.97%) ▲|MU905.25+26.41 (+3.00%) ▲|NEE78.35-1.46 (-1.82%) ▼|NFLX69.52-1.01 (-1.43%) ▼|NKE37.11-0.03 (-0.07%) ▼|NOW144.64+2.67 (+1.88%) ▲|NVDA217.40+3.27 (+1.53%) ▲|ORCL130.04+1.81 (+1.41%) ▲|PEP133.22+1.73 (+1.32%) ▲|PFE29.47-0.12 (-0.39%) ▼|PG158.19-1.16 (-0.73%) ▼|PLTR194.27+8.24 (+4.43%) ▲|PM202.88-2.33 (-1.13%) ▼|QCOM173.54+1.43 (+0.83%) ▲|RTX193.17-0.75 (-0.39%) ▼|SBUX98.10+0.58 (+0.59%) ▲|SCHW89.99-1.97 (-2.14%) ▼|SO89.81-1.37 (-1.50%) ▼|SPG202.59-2.85 (-1.39%) ▼|T23.34-0.11 (-0.45%) ▼|TMO679.81-10.19 (-1.48%) ▼|TMUS157.88-1.22 (-0.77%) ▼|TSLA368.00+13.28 (+3.74%) ▲|TXN276.41-0.08 (-0.03%) ▼|UBER70.33-0.03 (-0.04%) ▼|UNH405.18+3.75 (+0.93%) ▲|UNP287.87-1.17 (-0.40%) ▼|UPS97.15-0.33 (-0.34%) ▼|USB58.17-0.57 (-0.96%) ▼|V403.61+1.00 (+0.25%) ▲|VZ44.38-0.41 (-0.92%) ▼|WFC82.48-1.39 (-1.66%) ▼|WMT119.22+0.41 (+0.34%) ▲|XOM178.67-0.31 (-0.17%) ▼|
18 C
New York
Monday, October 19, 2026

Tag: treatment

newssourceFORcompanycontentinformation1releasesmarket

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson’s Disease

Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson's Disease

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain...

TAIPEI, June 11, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil...

Cynosure Lutronic’s XERF™, Worldwide Adoption Accelerates, Now 3x Faster

Now among the fastest-scaling monopolar RF devices worldwide, XERF™ has more than tripled its pace of adoption in recent months with Asia-Pacific and North...

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

DKSH Enters Strategic Distribution Partnership with BridgeBio to Support Regulatory Evaluation and Potential Patient Access to Transthyretin Stabilizer for ATTR-CM in Selected Asia Pacific...

SINGAPORE, June 11, 2026 /PRNewswire/ -- DKSH entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient access to a...

Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update

Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results
and Provides Business Update

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8

NEW TAIPEI CITY, June 10, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial...

Coordinated Care, Sea Mar Community Health Centers, and the University of Washington Announce First Scholarship Recipient of New Endowment to Bolster the State’s Dental...

Scholarship aims to support students of color pursuing careers in dentistry to improve access to representative oral care across the state. SEATTLE, June 10,...

CRIN Funds 11 Projects through the Accelerating Cleantech Innovation Competition

CALGARY, AB, June 10, 2026 /CNW/ - The Clean Resource Innovation Network (CRIN) will fund 11 new innovative projects as part of the Accelerating...

SafeSpace Global Announces Launch of New Addiction Treatment Vertical, Supported by Signed Master Services Agreement and Conditional $2 Million Funding Commitment

KNOXVILLE, TN, June 10, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (“SafeSpace Global” or the “Company”), a provider of AI-powered physical safety and security solutions for regulated care environments, today announced the launch of its new Addiction Treatment Vertical, supported by a newly executed Master Services Agreement (“MSA”) with Antidote Health Ventures and a conditional funding commitment from Method Five Labs, LLC (“Method Five Labs”).

Canada Nickel Completes Upsized Non-Brokered Private Placement of Flow-Through Shares and Provides Corporate Update

/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./TORONTO, June 10, 2026 /CNW/ - Canada...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatment

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers